These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25056809)

  • 1. Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.
    Morgentaler A; McGettigan J; Xiang Q; Danoff TM; Gould EM
    Int J Impot Res; 2015; 27(2):41-5. PubMed ID: 25056809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A; Norwood P; Potts S; Gould E; Chitra S
    J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism.
    Miller J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Endocr Pract; 2011; 17(4):574-83. PubMed ID: 21454244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new testosterone gel (fortesta) for hypogonadism.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):29-30. PubMed ID: 21502933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
    Rogol AD; Tkachenko N; Bryson N
    Andrology; 2016 Jan; 4(1):46-54. PubMed ID: 26695758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men.
    Ross RJ; Jabbar A; Jones TH; Roberts B; Dunkley K; Hall J; Long A; Levine H; Cullen DR
    Eur J Endocrinol; 2004 Jan; 150(1):57-63. PubMed ID: 14713280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel testosterone 2% gel for the treatment of hypogonadal males.
    Dobs AS; McGettigan J; Norwood P; Howell J; Waldie E; Chen Y
    J Androl; 2012; 33(4):601-7. PubMed ID: 21979302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption of testosterone gel 1% (Testim) from three different application sites.
    Guay AT; Smith TM; Offutt LA
    J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.
    Kaufman JM; Miller MG; Garwin JL; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.
    Dobs AS; Matsumoto AM; Wang C; Kipnes MS
    Curr Med Res Opin; 2004 May; 20(5):729-38. PubMed ID: 15140340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone supplementation for hypogonadal men by the nasal route.
    Mattern C; Hoffmann C; Morley JE; Badiu C
    Aging Male; 2008 Dec; 11(4):171-8. PubMed ID: 19172548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of Testim gel.
    McNicholas T; Ong T
    Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men.
    Muram D; Ni X
    Curr Med Res Opin; 2016; 32(2):263-9. PubMed ID: 26549704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
    Wang C; Swerdloff R; Kipnes M; Matsumoto AM; Dobs AS; Cunningham G; Katznelson L; Weber TJ; Friedman TC; Snyder P; Levine HL
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3821-9. PubMed ID: 15292312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
    Meikle AW; Matthias D; Hoffman AR
    BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
    Cunningham G; Belkoff L; Brock G; Efros M; Gittelman M; Carrara D; Neijber A; Ando M; Mitchel J
    Endocr Pract; 2017 May; 23(5):557-565. PubMed ID: 28225313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparability of single measurements of serum testosterone to the 24-hour C(avg) in patients using testosterone 2% solution.
    Muram D; Baygani S
    J Sex Med; 2014 Nov; 11(11):2826-9. PubMed ID: 25123851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.